CROUSDT
Crypto.com Coin / Tether USD
crypto Composite

This is awesome! How much of that is in 4 year staking at 11.44%? My goal is to reach 516K CRO then I’m good.

I’ve been a scientist in biotech for a decade and I currently work in the Boston startup ecosystem. I used to purchase reagents/materials from Boston Scientific when I first started and I now I don’t purchase anything from them and they’re not even a partner vendor in my companies procurement software. They are 20 miles away yet we prefer chinese vendors and CROs. Unless they’ve completely pivoted to something else, they’ve faded out of my field as a supplier and I haven’t heard anyone mention them in years. Fisher, Sigma, Promega, and Revitty run the materials game. Pharmaron and WuXi run the CRO game.

**$RHEL / Rhelion Life Sciences**
I’ve spent a lot of time digging into Rhelion lately and there’s actually quite a bit that could happen between now and the end of 2026.
Obviously none of this is guaranteed, especially with a company this size, but these are the main things I’m watching.
**1. DARMYIAN**
This is probably the **biggest one for me.**
Rhelion/Filament signed a non-binding LOI with Darmiyan in August to look at using PEX010 alongside Darmiyan’s BrainSee AI technology in a potential Alzheimer’s clinical program.
Darmiyan is interesting because BrainSee already has **FDA De Novo authorization** and the company has some legitimate backing behind it.
The next step would obviously be getting past the LOI and into a **definitive agreement.**
If that happens and they actually lay out a clinical development plan, I think that would be a pretty meaningful catalyst for RHEL.
**2. PEX010 FOR COCAINE-USE DISORDER**
This is the other major one I’m watching closely.
There was a randomized study published this year showing some very encouraging results for psilocybin in cocaine-use disorder.
Filament has rights tied to the study data and associated IP, and Rhelion has already said they’re actively exploring moving PEX010 into a **Phase 2b program.**
They’ve mentioned:
**Trial design**
**CRO selection**
**Regulatory pathways**
**Financing**
So at this point I’d be watching for any real movement there.
A formal **Phase 2b plan, regulatory update, financing announcement or actual timeline** would be a big step forward.
**3. IBEX011**
This one probably isn’t getting as much attention.
Filament has already developed IBEX011, which is their standardized botanical iboga extract.
In the August 31 update Todd Shapiro said they expect to provide another update on the program *“in the near future.”*
That makes me think there’s a decent chance we hear something before year end.
**4. PEX010 CLINICAL TRIALS**
PEX010 is now being used or supplied into a growing number of studies including programs involving the:
**University of Washington**
**University Health Network**
**University of Melbourne**
**UCSF** and others.
Rhelion has said PEX010 is supporting **more than 80 academic and philanthropic studies around the world.**
Any first-patient dosing announcements, trial commencements, new shipments, new universities or additional indications would all be positives.
**5. GERMANY + INTERNATIONAL EXPANSION**
The Germany compassionate-use program is another thing I’m watching.
They’ve already shipped more PEX010 into Germany.
I don’t think the current revenue from that is really the main story.
What matters to me is that they’re proving they can manufacture **pharmaceutical-grade psilocybin in Canada** and move it into regulated markets internationally.
If they announce another country, another compassionate-use program or some type of commercial supply agreement, that becomes a lot more interesting.
**6. PATENT PORTFOLIO / LICENSING**
The patent portfolio also continues to grow.
Filament now has **77 issued patents across 13 patent families.**
Another patent isn’t necessarily going to move the stock much by itself.
But an actual **licensing or commercialization agreement** tied to that IP definitely could.
**7. LEGACY ASSET SALES**
Legacy assets are another potential source of news.
Management has been trying to clean up the old Red Light Holland side of the business and focus more heavily on life sciences.
They’ve been looking at strategic options for **MiniChamp and the Ontario farmland/assets.**
If they can sell non-core assets and bring cash into the company **without issuing more shares**, that would obviously be a positive.
**8. NEXT FINANCIAL RESULTS**
I’m also interested in the next financial results.
I’m not really looking at revenue at this point as much as I’m looking at:
**Cash burn**
**R&D spending**
**Filament integration costs**
**Liquidity**
They had roughly **C$2.6M cash and C$5M in short-term GIC investments** as of June 30.
For a company this size, protecting that balance sheet while moving the pipeline forward is important.
**9. ANOTHER PARTNERSHIP OR ACQUISITION**
The wildcard would be another acquisition, licensing deal or strategic partnership.
Management has already said they’re looking at opportunities that could complement Filament.
There’s nothing specific announced right now, but it’s something I’ll be watching.
**MY TOP CATALYSTS**
If I had to rank the ones I care about most:
**1. Darmiyan definitive agreement / Alzheimer’s development plan**
**2. PEX010 Phase 2b cocaine-use-disorder program**
**3. Major licensing or pharma partnership**
**4. IBEX011 update**
**5. New PEX010 trials or major trial progress**
**6. Sale of legacy assets**
**7. Next quarterly financial update**
What I find interesting about RHEL is that the story is completely different now than the old Red Light Holland story.
They now own **Filament, PEX010, the manufacturing platform, a large patent portfolio and a drug that’s already being supplied into dozens of research programs.**
Now management actually has to execute.
If a couple of the bigger catalysts come together before the end of the year, I think **RHEL could enter 2027 looking like a very different company.**
If they don’t, then the big question becomes how long shareholders are willing to wait and how quickly cash gets burned in the meantime.
That’s basically how I’m looking at it.
**Anyone else following RHEL closely?**
*What do you think is the most likely catalyst we actually see before the end of the year?*

It said .0000125% an hour for CRO

Nice to see, it’s a good average to be sat at, plus depending upon where you are, and how you set your staking up, you should have nice weekly rewards!
Your net invested at $142.43K looks high though compared to mine with a similar amount of CRO??

Alright talk me off the ledge if this is a bad idea.
I’ve been selling my rewards for btc the last few months. Now I have a different idea.
Kraken offers up to 10x leverage on CRO futures for a “reasonable” fee. Why not transfer my rewards and use 2-3x leverage to buy and hold CRO until we reach new ATHs?

I'm in it for the long haul. I believe in the entire crypto market cap increasing over time. CRO will rise with it and be my retirement bridge.